Introduction:
The Indian pharmaceutical industry has witnessed remarkable growth in 2024, with India leading the global market as the largest supplier of generic drugs, holding a 20% share by volume. This growth is driven by rising demand for generics, improved healthcare infrastructure, and supportive government policies.
Also read: Ambani stock to buy now that can deliver returns of 20%; Do you own it?
A higher Return on Capital Employed (RoCE) reflects better capital efficiency, while a higher Return on Equity (RoE) indicates increased profitability from shareholder investments. Using both RoCE and RoE together provides a comprehensive view of a company’s financial health and performance.
Sanofi Consumer Healthcare India Ltd
As of November 14, 2024, Sanofi Consumer Healthcare India Ltd. saw its share price fluctuate from ₹4,350 at the opening to a high of ₹5,499 and a low of ₹4,212, closing at ₹4,818. The company’s market cap stands at ₹11,097 crore.
Despite the price movement, the stock recorded a slight change of -0.09%. Key financial metrics show an impressive Return on Equity (ROE) of 51.54% and Return on Capital Employed (ROCE) of 71.10%, reflecting strong profitability and operational efficiency.
Sanofi Consumer Healthcare India Ltd is a leading pharmaceutical company in India, focusing on providing innovative and effective consumer healthcare products. It offers a range of products across categories like nutrition, allergy, pain relief, and digestive health, improving the quality of life for millions of consumers.
Also Read: 3 Stocks in which Ashish Kacholia bought fresh stake in Q2
GlaxoSmithKline Pharmaceuticals Ltd
As of November 14, 2024, GlaxoSmithKline Pharmaceuticals Ltd.’s share price fluctuated between ₹1,565 and ₹3,088, closing at ₹2,457. The stock experienced a slight gain of +0.14%. With a market cap of ₹41,626 crore, the company maintains a strong position in the pharmaceutical sector.
It boasts an impressive Return on Equity (ROE) of 37.32% and Return on Capital Employed (ROCE) of 51.33%, highlighting its strong profitability and operational efficiency.
GlaxoSmithKline Pharmaceuticals Ltd (GSK) is a global healthcare company committed to improving the quality of human life through innovative medicines, vaccines, and consumer healthcare products. In India, GSK focuses on areas like respiratory, dermatology, and pain management, offering high-quality products to meet the needs of diverse patients.
Abbott India Ltd
As of November 14, 2024, Abbott India Ltd’s share price ranged from ₹21,983 to ₹30,521, closing at ₹27,351, reflecting a decline of -1.08%. The company holds a market cap of ₹58,121 crore and a book value of ₹1,657 per share.
Abbott maintains strong profitability with a Return on Equity (ROE) of 34.88% and a Return on Capital Employed (ROCE) of 46.02%, indicating efficient capital utilization and robust financial performance.
Abbott India Ltd is a subsidiary of the global healthcare company Abbott Laboratories. It is known for providing high-quality healthcare products in areas such as nutrition, diagnostics, medical devices, and branded generic pharmaceuticals. Abbott India aims to support better health outcomes for people across the country through its innovative solutions.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
